Gå direkt till huvudinnehållet

Reumatoid artrit, RA

Senast uppdaterad: Senast reviderad:
Sakkunnig:


Definition:
En kronisk, inflammatorisk sjukdom som framförallt drabbar leder i händer och fötter.
Förekomst:
Prevalensen uppskattas till ca 0,7 % i Sverige.
Symtom:
Symmetriska ledinflammationer, särskilt i händer och fötter, men alla leder kan drabbas. Allmänsymtom är vanligt.
Kliniska fynd:
Vid nydebuterad RA ses ofta artriter i MCP-, PIP- och MTP-leder, men debut med mono- eller oligoartrit i andra leder förekommer.
Diagnostik:
Viktiga tilläggsundersökningar är anti-CCP, RF, SR, CRP och röntgen.
Behandling:
Centralt i behandlingen är syntetiska DMARDs och biologiska DMARDs.
  1. Wasserman AM. Diagnosis and management of rheumatoid arthritis. Am Fam Physician 2011; 84: 1245-52. PMID: 22150658 PubMed  
  2. Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Seminar. Lancet 2010; 376: 1094-1108. PubMed  
  3. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998; 41: 778-81. PubMed  
  4. Neovius, M., Simard, J. F., Askling, J. Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden. Ann Rheum Dis, 2011;70, 624-9. pmid: 21149495. PubMed  
  5. Alamanos, Y., Voulgari, P. V., Drosos, A. A. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum 2006; 36, 182-8.pmid: 17045630. PubMed  
  6. Gabriel, S. E., Crowson, C. S., O'Fallon, W. M. The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955-1985. Arthritis Rheum 1999; 42, 415-20. PMID: 10088762 PubMed  
  7. Holmqvist, M. E., Wedren, S., Jacobsson, L. T., Klareskog, L., Nyberg, F., Rantapää-Dahlqvist, S., et al. Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006. J Intern Med 2010; 268, 578-585.
  8. Ajeganova S, Andersson ML, Hafström I; for the BARFOT Study Group.Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: A long-term followup from disease onset.Arthritis Care Res (Hoboken). 2013 Jan;65(1):78-87. PubMed  
  9. Söderlin, M. K., Börjesson, O., Kautiainen, H., Skogh, T. & Leirisalo-Repo, M. Annual incidence of inflammatory joint diseases in a population based study in southern Sweden. Ann Rheum Dis 2002; 61, 911-5. PMID: 12228162 PubMed  
  10. Rantapää-Dahlqvist, S., de Jong, B. A., Berglin, E., Hallmans, G., Wadell, G., Stenlund, H., et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48, 2741-9. PMID: 14558078 PubMed  
  11. Schett, G., Firestein, G. S. Mr Outside and Mr Inside: classic and alternative views on the pathogenesis of rheumatoid arthritis. Ann Rheum Dis, 2010; 69, 787-9. PMID: 20299352 PubMed  
  12. Firestein, G. S. 2005. Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. J Clin Rheumatol, 11, S39-44. PMID: 16357749 PubMed  
  13. McInnes, I. B. & Schett, G. 2007. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol, 7, 429-42. PMID: 17525752 PubMed  
  14. Miossec, P., Korn, T. & Kuchroo, V. K. 2009. Interleukin-17 and type 17 helper T cells. N Engl J Med, 361, 888-98. PMID: 19710487 PubMed  
  15. McInnes, I. B. & Schett, G. 2011. The pathogenesis of rheumatoid arthritis. N Engl J Med, 365, 2205-19. PMID: 22150039 PubMed  
  16. Nakken, B., Munthe, L. A., Konttinen, Y. T., Sandberg, A. K., Szekanecz, Z., Alex, P., et al. 2011. B-cells and their targeting in rheumatoid arthritis--current concepts and future perspectives. Autoimmun Rev, 11, 28-34. PMID: 21777703 PubMed  
  17. MacGregor, A. J., Snieder, H., Rigby, A. S., Koskenvuo, M., Kaprio, J., Aho, K., et al. 2000. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum, 43, 30-7. PMID: 10643697 PubMed  
  18. Gregersen, P. K., Silver, J. & Winchester, R. J. 1987. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum, 30, 1205-13. PMID: 2446635 PubMed  
  19. Deighton, C. M., Walker, D. J., Griffiths, I. D. & Roberts, D. F. 1989. The contribution of HLA to rheumatoid arthritis. Clin Genet, 36, 178-82.PMID: 2676268 PubMed  
  20. van der Woude, D., Houwing-Duistermaat, J. J., Toes, R. E., Huizinga, T. W., Thomson, W., Worthington, J., et al. 2009. Quantitative heritability of anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis. Arthritis Rheum, 60, 916-23. PMID: 19333951 PubMed  
  21. de Vries, R. R., van der Woude, D., Houwing, J. J. & Toes, R. E. 2011. Genetics of ACPA-positive rheumatoid arthritis: the beginning of the end? Ann Rheum Dis, 70 Suppl 1, i51-4. PMID: 19333951 PubMed  
  22. Costenbader, K. H., Feskanich, D., Mandl, L. A. & Karlson, E. W. 2006. Smoking intensity, duration, and cessation, and the risk of rheumatoid arthritis in women. Am J Med, 119, 503 e1-9. PMID: 16750964 PubMed  
  23. Silman, A., Kay, A. & Brennan, P. 1992. Timing of pregnancy in relation to the onset of rheumatoid arthritis. Arthritis Rheum, 35, 152-5.PMID: 1734904 PubMed  
  24. Karlson, E. W., Mandl, L. A., Hankinson, S. E. & Grodstein, F. 2004. Do breast-feeding and other reproductive factors influence future risk of rheumatoid arthritis? Results from the Nurses' Health Study. Arthritis Rheum, 50, 3458-67. PMID: 15529351 PubMed  
  25. Berglin, E., Kokkonen, H., Einarsdottir, E., Agren, A. & Rantapaa Dahlqvist, S. 2010. Influence of female hormonal factors, in relation to autoantibodies and genetic markers, on the development of rheumatoid arthritis in northern Sweden: a case-control study. Scand J Rheumatol, 39, 454-60. PMID: 20560812 PubMed  
  26. Mikuls, T. R., Payne, J. B., Reinhardt, R. A., Thiele, G. M., Maziarz, E., Cannella, A. C., et al. 2009. Antibody responses to Porphyromonas gingivalis (P. gingivalis) in subjects with rheumatoid arthritis and periodontitis. Int Immunopharmacol, 9, 38-42. PMID: 18848647 PubMed  
  27. Rantapää-Dahlqvist, S., de Jong, B. A., Berglin, E., Hallmans, G., Wadell, G., Stenlund, H., et al. 2003. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum, 48, 2741-9. PMID: 14558078 PubMed  
  28. Aletaha, D., Neogi, T., Silman, A. J., Funovits, J., Felson, D. T., Bingham, C. O., 3rd, et al. 2010. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis, 69, 1580-8. PMID: 20872595 PubMed  
  29. Nishimura, K., Sugiyama, D., Kogata, Y., Tsuji, G., Nakazawa, T., Kawano, S., et al. 2007. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med, 146, 797-808. PMID: 17548411 PubMed  
  30. Payet J, Goulvestre C, Biale L, et al. Anticyclic Citrullinated Peptide Antibodies in Rheumatoid and Nonrheumatoid Rheumatic Disorders: Experience with 1162 Patients. J Rheumatol. 2014 Oct 1. pii: jrheum.131375. PMID: 25274898. PubMed  
  31. Ford JA, Marshall AA, Liu X, et al. Impact of Cyclic Citrullinated Peptide Antibody Level on Progression to Rheumatoid Arthritis in Clinically Tested Cyclic Citrullinated Peptide Antibody–Positive Patients Without Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2019; 71: 1583-92. pmid:30570827 PubMed  
  32. Tilstra JS, Lienesch DW. Rheumatoid Nodules. Dermatol Clin. 2015;33(3):361-71 PubMed  
  33. Combe, B., Landewe, R., Lukas, C., Bolosiu, H. D., Breedveld, F., Dougados, M., et al. 2007. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis, 66, 34-45. PMID: 16396980 PubMed  
  34. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR Recommendations for the Management of Rheumatoid Arthritis With Synthetic and Biological Disease-Modifying Antirheumatic Drugs: 2019 Update. Ann Rheum Dis 2020. pmid:31969328 PubMed  
  35. Nam JL, Ramiro S, Gaujoux-Viala C, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2014 Mar;73(3):516-28. doi: 10.1136/annrheumdis-2013-204577. PMID: 24399231 PubMed  
  36. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016 Oct 22;388(10055):2023-2038. PMID: 27156434. PubMed  
  37. Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015 Jul 18;386(9990):258-65. doi: 10.1016/S0140-6736(14)61704-9. PMID: 25975452 PubMed  
  38. Swärdh E, Brodin N. Effects of aerobic and muscle strengthening exercise in adults with rheumatoid arthritis: a narrative review summarising a chapter in Physical activity in the prevention and treatment of disease (FYSS 2016). Br J Sports Med. 2016 Mar;50(6):362-7. pmid: 26843536. PubMed  
  39. Proudman SM, James MJ, Spargo LD, et al. Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use. Ann Rheum Dis. 2013 Sep 30. PMID: 24081439 PubMed  
  40. Tedeschi SK, Bathon JM, Giles JT, et al. Relationship Between Fish Consumption and Disease Activity in Rheumatoid Arthritis. Arhtritis Care Res (Hoboken) 2018; 70: 327-32. pmid:28635117 PubMed  
  41. Stolt, P., et al., Quantification of the influence of cigarette smoking on rheumatoidarthritis: results from a population based case-control study, using incident cases.Ann Rheum Dis, 2003. 62(9): p. 835-41. PMID: 12922955 PubMed  
  42. Westhoff G, Rau R, Zink A. Rheumatoid arthritis patients who smoke have a higher need for DMARDs and feel worse, but they do not have more joint damage than non-smokers of the same serological group. Rheumatology 2008;47:849-54. PMID: 18390589 PubMed  
  43. Mattey, D. L., Brownfield, A., Dawes, P. T. Relationship between pack-year history of smoking and response to tumor necrosis factor antagonists in patients with rheumatoid arthritis. J Rheumatol, 2009;36: 1180-7. PMID: 19447930 PubMed  
  44. Gonzalez A, Maradit Kremers H, Crowson CS, Ballman KV, Roger VL, Jacobsen SJ, O’Fallon WM, Gabriel SE: Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis 2008, 67:64-69. PMID: 17517756 PubMed  
  45. Silverstein FE, Faich G, Goldstein JL, Simon LS, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and reumatoid arthritis. JAMA 2000; 284: 1247-55. Journal of the American Medical Association  
  46. Gustavo C Machado GC, Maher CG, Ferreira PH, et al.Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. BMJ 2015; 350 doi PMID: 25828856 PubMed  
  47. Kirwan, J. R., Bijlsma, J. W., Boers, M., Shea, B. J. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD006356. PMID: 17253590 PubMed  
  48. Iannone F, Lopalco G, Cantarini L, et al. Efficacy and safety of combination therapy for preventing bone damage in rheumatoid arthritis. Clin Rheumatol. 2016 Jan;35(1):19-23. Epub 2015 Nov 19. pmid: 26581205 PubMed  
  49. SRFs riktlinjer och rekommendationer. Svensk Reumatologisk Förening. svenskreumatologi.se  
  50. Lopez-Olivo MA, Siddhanamatha HR, Shea B, et al. Methotrexate for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2014 Jun 10;6:CD000957. doi: 10.1002/14651858.CD000957.pub2. PMID: 24916606 PubMed  
  51. Shea B, Swinden MV, Tanjong Ghogomu E, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2013 May 31;5. PMID: 23728635. PubMed  
  52. Hazlewood GS, Barnabe C, Tomlinson G, et al. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. BMJ 2016; Apr 21;353: i1777. pmid:27102806 PubMed  
  53. Leumbruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009; 68: 1136-45. PubMed  
  54. van Vollenhoven RF, Emery P, Bingham CO 3rd, et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol. 2010; 37: 558-67. PubMed  
  55. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-tnf antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85 Journal of the American Medical Association  
  56. Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum 2006;54:2807-16. PubMed  
  57. Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf. 2011 Feb;20(2):119-30. doi: 10.1002/pds.2046. Epub 2010 Dec 7. PMID: 21254282 PubMed  
  58. Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: A randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response tomethotrexate (study evaluating rituximab's efficacy in mtx inadequate responders (serene)). Ann Rheum Dis 2010;69:1629-35. PubMed  
  59. Lopez-Olivo MA, Amezaga Urruela M, McGahan L, et al. Rituximab for rheumatoid arthritis. Cochrane Database Syst Rev. 2015 Jan 20;1:CD007356. PMID: 25603545. PMID: 25603545 PubMed  
  60. Ljung L, Smeds J, Persson G, Jirlen L, Toolanen G. Immunsuppression kan maskera allvarlig infektion. Septisk artrit under tocilizumabbehandling gav endast blygsam akutfasreaktion. Läkartidningen. 2012 Sep 19-26;109(38):1678-9.
  61. Xie F, Yun H, Bernatsky S, Curtis JR. Risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments. Arthritis Rheumatol 2016; 68: 2612. pmid:27213279. PubMed  
  62. Chung CP, Sokka T, Arbogast PG, Pincus T. Work disability in early rheumatoid arthritis: higher rates but better clinical status in Finland compared with the US. Ann Rheum Dis. 2006 Dec;65(12):1653-7. Epub 2006 Jun 1. PMID: 16740683 PubMed  
  63. Turesson, C., O'Fallon, W. M., Crowson, C. S., Gabriel, S. E., Matteson, E. L. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis 2003; 62:722-7. PubMed  
  64. Huang S, Doyle TJ, Hammer MM, et al. Rheumatoid arthritis-related lung disease detected on clinical chest computed tomography imaging: Prevalence, risk factors, and impact on mortality. Semin Arthritis Rheum 2020; 50:1216. PMID: 33059295 PubMed  
  65. Meune C, Touze E, Trinquart L, et al. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology 2009; 48: 1309-13.
  66. Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015 Mar;74(3):480-9. doi: 10.1136/annrheumdis-2014-206624. PMID: 25561362 PubMed  
  67. Södergren, A., Stegmayr, B., Lundberg, V., Öhman, M. L. & Wållberg-Jonsson, S. 2007. Increased incidence of and impaired prognosis after acute myocardial infarction among patients with seropositive rheumatoid arthritis. Ann Rheum Dis, 66, 263-6. PMID: 16854951 PubMed  
  68. Lindhardsen J, Ahlehoff O, Gislason GH, et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis 2011; 70: 929-934. PubMed  
  69. Holmqvist, M., Gransmark, E.,Mantel, A., Alfredsson, L., Jacobsson, L. T., Wållberg-Jonsson, S., Askling, J. Occurrence and relative risk of stroke in incident and prevalent contemporary rheumatoid arthritis. Ann Rheum Dis 2012 May 18. Epub ahead of print PMID: 22610975 PubMed  
  70. Lindhardsen J, Ahlehoff O, Gislason GH, Madsen OR, Olesen JB, et al. Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish nationwide cohort study. BMJ. 2012 Mar 8;344:e1257. doi: 10.1136/bmj.e1257. PMID: 22403267 PubMed  
  71. Giles, J. T., Malayeri, A. A., Fernandes, V., Post, W., Blumenthal, R. S., Bluemke, D., Vogel-Claussen, J., et al. Left ventricular structure and function in patients with rheumatoid arthritis, as assessed by cardiac magnetic resonance imaging. Arthritis Rheum 2010; 62: 940-51 PubMed  
  72. Mantel A, Holmqvist M, Andersson DC et al. Association Between Rheumatoid Arthritis and Risk of Ischemic and Nonischemic Heart Failure. J Am Coll Cardiol 2017; 69(10): 1275-85. pmid:28279294 PubMed  
  73. Scott DL, Steer S. The course of established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2007 Oct;21(5):943-67. PubMed  
  74. Wållberg-Jonsson, S., Öhman, M. L., Rantapää-Dahlqvist, S. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 1997; 24:445-51.
  • Tomas Zweig, överläkare, Reumatologkliniken, Karolinska Universitetssjukhuset, Solna
  • Anna Nager, med dr och specialist i allmänmedicin, Karolinska institutet